Ossiam Sells 4,709,790 Shares of Pfizer Inc. $PFE

Ossiam trimmed its position in Pfizer Inc. (NYSE:PFE) by 83.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 940,783 shares of the biopharmaceutical company’s stock after selling 4,709,790 shares during the quarter. Ossiam’s holdings in Pfizer were worth $23,971,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in PFE. Mangrove Partners IM LLC bought a new position in shares of Pfizer in the 3rd quarter valued at about $844,000. Siemens Fonds Invest GmbH raised its stake in shares of Pfizer by 3.9% during the third quarter. Siemens Fonds Invest GmbH now owns 230,597 shares of the biopharmaceutical company’s stock worth $5,876,000 after buying an additional 8,560 shares during the last quarter. NorthRock Partners LLC lifted its holdings in Pfizer by 14.7% in the third quarter. NorthRock Partners LLC now owns 76,478 shares of the biopharmaceutical company’s stock valued at $1,949,000 after buying an additional 9,827 shares during the period. Prudential PLC lifted its holdings in Pfizer by 0.3% in the third quarter. Prudential PLC now owns 793,527 shares of the biopharmaceutical company’s stock valued at $20,219,000 after buying an additional 2,600 shares during the period. Finally, Texas Capital Bancshares Inc TX bought a new position in Pfizer in the third quarter valued at approximately $64,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the topic of a number of analyst reports. BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Monday. Morgan Stanley dropped their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research report on Thursday, February 12th. Finally, Barclays initiated coverage on Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.05.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.60 on Friday. The stock’s fifty day simple moving average is $26.50 and its 200 day simple moving average is $25.52. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $151.23 billion, a PE ratio of 19.56 and a beta of 0.47. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.63 earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.